SCHEMBL6522983

SCHEMBL6522983

O=C(O)c1ccc(CNc2ccc3c(=O)[nH]c4ncccc4c3c2)cc1

nearest known ligand 0.49

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 2/20 0.49
AURKA O14965 1/20 0.49
CAMKK2 Q96RR4 1/20 0.46
HDAC6 Q9UBN7 2/20 0.46
IP6K1 Q92551 1/20 0.44
HAO1 Q9UJM8 1/20 0.44
DHFR P00374 2/20 0.42
CDC7 O00311 1/20 0.42
DBF4 Q9UBU7 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3454371 0.88 AURKA (0.60) PARP1AURKAIP6K1HAO1CDC7
SCHEMBL6525385 0.88 CA1 (0.50) PARP1AURKAHDAC6
SCHEMBL6519406 0.85 AURKA (0.52) PARP1AURKAIP6K1CDC7DBF4
SCHEMBL6521930 0.85 PARP1 (0.52) PARP1AURKAIP6K1CDC7DBF4
SCHEMBL6522266 0.85 AURKA (0.55) PARP1AURKAIP6K1CDC7DBF4
SCHEMBL6518086 0.83 AURKA (0.60) PARP1AURKAIP6K1HAO1CDC7
SCHEMBL6517391 0.82 AURKA (0.49) PARP1AURKAHDAC6IP6K1CDC7
SCHEMBL6527186 0.82 MAPT (0.51) PARP1AURKACDC7
SCHEMBL6521606 0.82 RPS6KB1 (0.47) PARP1AURKACAMKK2HDAC6IP6K1
SCHEMBL6516089 0.81 AURKA (0.54) PARP1AURKAIP6K1CDC7DBF4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
WO-2009108670-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK SERONO S.A. (CH) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MAP4K2, MAP3K20, MAP4K1 PARP1 1693/4885AURKA 538/4885CAMKK2 162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.